Shared Decision-making for Selection of FDA-approved Therapies for NMOSD

Author(s):

Key Takeaways

AQP4-IgG+ NMOSD treatment has advanced with targeted therapies, notably anti-CD20 agents like rituximab, have led to increased relapse rates.
The clinical significance of these findings emphasizes personalized treatment strategies, offering improved disease management and patient care.
In practice, these data support the integration of novel therapies into standard protocols, aligning with observed improvements in patient outcomes.

A panelist discusses how when treating NMOSD, neurologists should consider the patient's clinical characteristics, safety profiles, administration requirements, and cost-effectiveness when selecting between FDA-approved therapies such as eculizumab, inebilizumab, satralizumab, ravulizumab, and rituximab. Shared decision-making is crucial, involving close collaboration between the healthcare team and the patient to develop a personalized treatment plan that considers the patient's overall well-being.

EP: 1.Current Treatment Landscape of AQP4-IgG+ NMOSD and Considerations on Relapse Rates

Now Viewing

EP: 2.Shared Decision-making for Selection of FDA-approved Therapies for NMOSD

Video content above is prompted by the following:

What factors should be considered when choosing between other available FDA-approved therapies (eculizumab, inebilizumab, satralizumab, and ravulizumab) for patients with NMOSD?
What clinical characteristics can help guide neurologists in selecting eculizumab or ravulizumab versus rituximab?
Discuss shared decision-making when managing patients with APQ4+ NMOSD.